Protocol Title: A Phase III, Randomized, Open-Label, Multicenter, Global Study of
Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum
plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural
Mesothelioma (eVOLVE-Meso)
Protocol Number: D7988C00001
Book Here